<ul>

<li class="typography-body-regular">Emyria has received approval for a groundbreaking trial on MDMA-assisted therapy for PTSD. Their unique partnership with the PAX Centre sets them apart as one of the only groups in Australia offering comprehensive trauma-focused psychiatric services, ensuring patient safety. Emyria advocates integrating psychedelic therapies into mental health services for maximum protection. With trained therapists, a reliable drug supply, and an ethics-approved protocol, Emyria and PAX expand treatment options for PTSD patients.</li>

<li class="typography-body-regular">Starting July 1st, 2023, Australia will be the first country to recognise MDMA as a medicine, creating an opportunity for Emyria to lead globally in this field. The trial aims to develop a safe, community-based program for people with PTSD resistant to standard therapies while gathering real-world data to inform drug development.</li>

</ul>